Galera Therapeutics Performance
| GRTXDelisted Stock | USD 2.58 0.19 6.86% |
The company retains a Market Volatility (i.e., Beta) of -0.58, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Galera Therapeutics are expected to decrease at a much lower rate. During the bear market, Galera Therapeutics is likely to outperform the market. Galera Therapeutics right now retains a risk of 0.0%. Please check out Galera Therapeutics standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Galera Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Galera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Galera Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 4.3 M |
Galera |
Galera Therapeutics Relative Risk vs. Return Landscape
If you would invest 258.00 in Galera Therapeutics on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Galera Therapeutics or generate 0.0% return on investment over 90 days. Galera Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Galera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galera Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galera Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Galera Therapeutics, and traders can use it to determine the average amount a Galera Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GRTX |
Based on monthly moving average Galera Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galera Therapeutics by adding Galera Therapeutics to a well-diversified portfolio.
Galera Therapeutics Fundamentals Growth
Galera Stock prices reflect investors' perceptions of the future prospects and financial health of Galera Therapeutics, and Galera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galera Stock performance.
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) | ||||
| Cash And Equivalents | 52.01 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 152.3 M | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | (2.48) X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Total Asset | 26.14 M | ||||
| Retained Earnings | (437.41 M) | ||||
| Current Asset | 36.65 M | ||||
| Current Liabilities | 5.37 M | ||||
About Galera Therapeutics Performance
Evaluating Galera Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Galera Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Galera Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.Things to note about Galera Therapeutics performance evaluation
Checking the ongoing alerts about Galera Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galera Therapeutics is not yet fully synchronised with the market data | |
| Galera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (59.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galera Therapeutics currently holds about 52.01 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94. | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Galera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Galera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galera Therapeutics' stock. These opinions can provide insight into Galera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Galera Stock
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |